Confirmed Speakers

The International Congress of Immunology 2016 Organising Committee are pleased to announce the following speakers have confirmed their participation at the Congress:


Rafi Ahmed

Rafi Ahmed_smallDr. Rafi Ahmed is a Georgia Research Alliance Eminent Scholar and Director of the Emory Vaccine Center at Emory University School of Medicine in Atlanta, GA. His research efforts are directed towards: 1. Understanding the mechanisms of immunological memory and using this knowledge to develop new and more effective vaccines. 2. Defining the mechanisms of T cell exhaustion during chronic viral infections and cancer and developing strategies for restoring function in exhausted T cells. Dr. Ahmed is a member of the U.S. National Academy of Sciences and of the Institute of Medicine.

Cezmi Akdis 

Cezmi AdkisProf Cezmi Akdis is Director of the Swiss Institute of Allergy and Asthma Research (SIAF), Davos and Professor in Zurich University Medical Faculty. His research is focused on immune tolerance mechanisms in humans, developing novel vaccines and treatment modalities, and regulation and role of tissue cells and epithelial barrier in asthma and allergies. He has been continuously performing human immunology, lung and skin research to find solutions for allergies and asthma. Prof Akdis is Editor-in-Chief of the Journal of Allergy and Clinical Immunology.  He was president of the European Academy of Allergy Clinical Immunology (2011-2013), has received 13 international honors and awards and published more than 300 articles in peer-reviewed journals, 14 book chapters and 98 unreviewed articles. 

Shizuo Akira

Shizio Akira_smallShizuo Akira is director of WPI Immunology Frontier Research Center at Osaka University, Japan. After two years of postdoctoral working in Department of Immunology, UC Berkeley, he studied on IL-6 gene regulation and signalling in Osaka University. He was a professor in Department of Biochemistry, Hyogo College of Medicine from 1996 to 1999, where he became involved in Toll-like receptors research. By generating TLR family knockout mice, he identified ligands of many TLR members and clarified their signalling pathways. His current research interests are molecular mechanisms of innate immunity and inflammation, which are studied mainly by generating knockout mice.

Matthew Albert

Dr Matthew Albert
Institut Pasteur
Department of Immunology

More information coming soon.

Jim Allison

James P. AllisonJames Allison studies the regulation of T cell responses. He identified  CTLA-4 as a molecule that acts to limit T cell responses. He was the first to propose that blockade of the inhibitory signals mediated by CTLA-4 could enhance T cell responses to achieve tumor eradication.  He conducted the preclinical work with a CTLA-4 targeted antibody that led to its clinical development and eventual approval as a standard of care therapy for the treatment of patients with melanoma. He is now focused on developing novel combination strategies of immune checkpoint blockade to enhance efficacy and broaden application of this strategy for cancer therapy.

Sebastian Amigorena

Portrait de S. AmigorenaSebastian Amigorena studied biology and biochemistry in Paris (Université Paris 7), and obtained his PhD in 1990, before leaving in 1992 for a 3 year post-doc at Yale Medical School (New Haven, in Ira Mellman’s lab). He returned to Paris in 1995 and started an Inserm AVENIR group together with Christian Bonnerot. Today, he is the head of the Immunology Department (Institut Curie/ INSERM U932, “Immunity and Cancer”) at Institut Curie. Sebastian AMIGORENA was elected to the French “Academie des Sciences” in 2005.Sebastian Amigorena’s main scientific interest overlaps immunology and cell biology. In his graduate and post-doctoral studies, he analyzed the functions of IgG receptors and described the molecular basis of their inhibitory properties. He made several contributions to our understanding of antigen presentation and cross presentation in dendritic cells. His team analyzed dendritic cells’ endocytic pathway and described several unique specializations of their phagocytic pathway, including for the regulation of phagosome acidification, antigen export to the cytosol and the interactions of phagosomes with the Endoplasmic Reticulum. His team also used 2-photon intravital microscopy to analyzed cytotoxic T cells dynamics during the initiation of immune responses in lymph nodes and during the invasion and rejection of solid tumors. He also investigated the role of regulatory T cells in the control of the avidity of primary CD8+ T cell responses and in the development of memory T cells during infection.

Ido Amit

Ido Amit_smallIdo Amit is Assistant Professor at the Immunology Department, Weizmann Institute of Science. During his PhD, Amit successfully used systems biology approaches to study cancer in a way that integrated classical biochemistry and a physiological understanding of the way tumours develop. His Postdoctoral research at the Broad institute has shown how regulatory networks of genes and chromatin control the formation of cellular blood components (hematopoiesis) and the immune response. Recently, using single cell analysis and genomic methods, Amit and colleagues were able to provide a comprehensive model of chromatin dynamics during blood development. Using hematopoiesis as a model to study chromatin state dynamics, Amit’s team identified approximately 50,000 hematopoietic enhancer regions and characterized their dynamics. The work allowed them to uncover the regulatory regions utilized in blood cell development and set the grounds to identify regulatory regions involved in many diseases by applying similar approaches in human cohorts. Among others, he is a recipient of a Starting Scientist Award by the European Research Council, has received the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine and the 2015 EMBO Gold Medal for his work to reveal the function of the immune system.

Ana Anderson

Ana Anderson_smallDr. Anderson obtained her Ph.D. in Immunology from Harvard University and is currently Assistant Professor of Neurology at Harvard Medical School and Associate Scientist at the Brigham and Women’s Hospital. Dr. Anderson’s laboratory works in the field of cancer immunology, specifically on the role of co-inhibitory receptors in the regulation of anti-tumor immunity. Her laboratory identified the co-inhibitory receptor Tim-3 as a key regulator of T cell dysfunction in cancer. Dr. Anderson has published over 60 original papers, reviews, and book chapters. She is a core faculty member of the Evergrande Center for Immunologic Diseases and serves on the editorial boards for OncoImmunology and Cellular Immunology.

Giovanna Barba Spaeth 

Institut Pasteur

More details coming soon.

Facundo Batista

Facundo Batista_small

Facundo D Batista obtained his biology degree at the University of Buenos Aires, Argentina. He then moved to Italy were he achieved his MSc and Ph.D. working in the laboratory of Oscar Burrone at the International  Centre for Genetic Engineering  and Biotechnology, Trieste. He was awarded a long-term EMBO fellowship to investigate the relationship between antigen affinity and the outcome of B-cell activation, under Michael Neuberger guidance at the Laboratory of Molecular Biology, University of Cambridge, UK. During this time he showed that antigen must exceed a lower affinity threshold to trigger B-cell activation, and that the form of antigen influences this tightly regulated threshold. Furthermore, Facundo showed that B cells form an immunological synapse in response to membrane-bound antigen from where they extract and present antigen to T cells.

In 2002, Facundo established his own independent laboratory, The Lymphocyte Interaction Lab, at the London Research Institute, Cancer Research UK (former ICRF). Their research efforts focus primary in understanding the process of B cell activation and antibody generation. To achieve this they combined cutting edge imaging techniques together with biochemistry and genetics which allow them to study this process not only at high molecular resolution but also in vivo.

Throughout Facundo’s scientific career, his research has consistently been communicated in prominent and high-impact journals as well as often ‘highlighted’. He has been invited both to author reviews in the prestigious journals in the field, and to present at key international conferences, such as Keystone, AAI and ICI. Furthermore, Facundo serves as a member of the Editorial Board of four journals including Science, and regularly reviews manuscripts for key journals as well as international grant applications. As a PI one of his top priorities remains nurturing and inspiring promising young scientists. Out of work developed in his lab, in 2011, Facundo spanned out Blink Therapeutics, a biotech company of which he is the Scientific Founder as well as Board Director. In recognition of these achievements, Facundo was elected to the EMBO Young Investigator Programme in 2004 and has since been awarded EMBO membership and the Royal Society Wolfson Research Merit Award as well as also becoming a Fellow of the Academy of Medical Science in the UK.

Yasmine Belkaid

Yasmine Belkaid_smallDr. Yasmine Belkaid obtained her Ph.D. in 1996 from the Pasteur Institute in France on innate responses to parasitic infection. Following a postdoctoral fellowship at NIAID on tissue immune regulation, she joined the Children’s Hospital Research Foundation in Cincinnati as an assistant professor. In 2005, she joined the Laboratory of Parasitic Diseases at NIAID and was appointed Senior Scientist in 2008. She is currently the chief of the Mucosal Immunology section. Yasmine Belkaid is a leader in the field of immune regulation. Her work has defined fundamental mechanisms that regulate host immune responses to pathogens at mucosal and skin sites and revealed key roles for commensal microbiota and dietary factors in the maintenance of tissue immunity and homeostasis.

Gabrielle Belz

Gabrielle Belz_smallGabrielle Belz originally trained in Veterinary medicine and surgery and received her PhD from the University of Queensland before undertaking postdoctoral training with Peter Doherty at St Jude Children’s Research Hospital where she developed an intense interest in how the immune system fights off infection. Gabrielle returned to the Walter and Eliza Hall Institute (Melbourne) as a Wellcome Trust Senior Overseas Fellow and established a program in pathogen infection to illuminate the complex interactions that occur between cells of the innate and adaptive immune system. Her research contributions have been recognized by a number of awards including a HHMI international fellowship and the Gottschalk Medal (Australian Academy of Science). Currently, she leads a research team that focuses on uncovering the cellular, transcriptional and epigenetic signals required to form long-lived protective immunity with a major focus on innate lymphocytes, dendritic cells and T cells.

Patricia Bozza

Patricia Bozza_cropped_smallPatricia Bozza obtained her M.D. from the State University of Rio de Janeiro and Ph.D. from the Instituto Oswaldo Cruz, Rio de Janeiro, Brazil. She was named a Pew Latin American Fellow in 1994 and went for a post-doc at Harvard Medical School under the mentoring of Peter Weller. Patricia returned to Brazil in 1997 to join the Instituto Oswaldo Cruz as an Associate Investigator. Patricia was named International Scholar from HHMI (2002-2006), Chair of the Pew Program in Biomedical Sciences Regional (Brazil) Committee in 2004 (2004-2008) and Guggenheim Fellow. She is an elected member of the Brazilian Academy of Sciences since 2013. She is currently Senior Investigator and Head of the Immunopharmacology Laboratory at Instituto Oswaldo Cruz. Patricia’s research interests focus on regulatory pathways of inflammation and lipid metabolism in host response to infection and other forms of inflammation.

Louise Boyle 

Louise Boyle_small

Louise Boyle received her PhD from the University of Cambridge in 2002. Since this time her research has mainly focused on MHC molecules. During her post-doctoral training in the laboratory of John Trowsdale she discovered an interaction between MHC class I and a novel tapasin-related protein called TAPBPR. In 2009, Louise was awarded a Wellcome Trust Career Development Fellowship to investigate the function of TAPBPR in the antigen presentation pathway. She is now a Wellcome Trust Senior Research Fellow at the University of Cambridge where her laboratory continues to dissect the molecular mechanisms controlling peptide selection for immune recognition.

Frank Brombacher

Frank Brombacher_cropped_smallProfessor Frank Brombacher studied Biology with a Diploma in bacterial genetics at the Alberts-Ludwigs University Freiburg, Germany in 1986 and a PhD in molecular immunology at the Max Planck Institute (MPI) in 1989, developing transgenic mice for B cell tolerance in the group of Nobel Laureate G. Koehler. After a Research Fellow time at Sandoz Ag (now Novartis), Switzerland, he was called back to the MPI as group leader in 1994, working on cytokine research and gene deficient mouse models. In 1998, he moved to the University of Cape Town, South Africa investigating on tuberculosis, African trypanosomiasis, leishmaniasis, helminthic infections and allergic diseases and since 2008 also coordinator for immunology & infectious diseases at the ICGEB Cape Town component.

Matthew Brown

Matthew Brown_smallMatt Brown is a clinician-scientist who trained initially as a rheumatologist before heading off into a career in immunogenetics research, initially at University of Oxford, but since 2005 at University of Queensland.  His particular interest is in the disease ankylosing spondylitis, where he has played a major role in the discovery of all non-MHC genes identified to be associated with the disease to date, as well as making contributions in the molecular and cellular mechanisms by which those genetic associations operate.  Since 2011 he has been Director of the UQ Diamantina Institute, and in 2013 was elected Fellow of the Australian Academy of Sciences for his services to medical research. In 2014 Matt ranked among ‘The world’s most influential scientific minds’ by multinational media body Thomson Reuters, with his research listed in the top 1% for the number of times his work has been cited by other scientists.

Meinrad Busslinger

Meinrad BusslingerMeinrad Busslinger is a founding member and scientific deputy director of the Research Institute of Molecular Pathology (IMP) in Vienna (Austria). His research is focused on the molecular mechanisms by which transcription factors control B cell development and function from lineage commitment to terminal plasma cell differentiation. An important discovery of his group was the first molecular description of a lineage commitment process by identifying Pax5 as the critical B cell identity factor. Meinrad Busslinger serves on editorial boards of international journals, is a member of the Austrian Academy of Sciences and received several awards including the Wittgenstein prize.

Xuetao Cao

Xuetao Cao_smallDr. Xuetao Cao, Professor and President of Chinese Academy of Medical Sciences, Beijing, China. He is now Professor and Director of National Key Laboratory of Medical Immunology (2006.5-), the president of FIMSA (Federation of Immunological Societies in Asia and Oceania) and President of Global Alliance for Chronic Diseases (GACD). His major interests are innate response and inflammation, immunobiology of APCs (dendritic cells, macrophages), and tumor immunology. As corresponding author, he published 226 original papers in peer-reviewed journals including Cell, Science, Nature Immunology, Cancer Cell, Immunity, J Exp Med, PNAS, etc. He is editorial board member of Cell, Annual Reviews of Immunology, Science Translational Medicine, eLife, etc.

Marco Colonna

Marco Colonna_smallMarco Colonna was born in Parma, Italy. He received his medical degree with specialization in Internal Medicine at Parma University. After postdoctoral training at Dana Farber Cancer Institute and Harvard Medical School he became a scientific member of the Basel Institute for Immunology in Basel, Switzerland, a leading center for immunology research. Since 2001 he has been a Professor of Pathology & Immunology at Washington University School of Medicine in St. Louis, MO. His laboratory is broadly interested in human innate immune responses during infections, autoimmunity and cancer. The laboratory generates mouse models to test hypotheses in vivo and provide proof of principle for interventions with the potential to be translated to human diseases. Research areas include: innate lymphoid cells in mucosal immunity; plasmacytoid dendritic cells and IFN-a/b in host defense and autoimmunity; innate immune mechanisms in Alzheimer’s disease.

Jason Cyster

Jason CysterJason Cyster is a Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. Cyster is an Immunologist recognized for his work on the cues guiding immune cell movements in lymphoid organs and for defining the mechanism of lymphocyte egress from tissues. He is also known for his use of real-time 2-photon microscopy to study immune cell migration and interaction dynamics within tissues during antibody responses. Cyster was born in Western Australia and grew up on a cattle farm in the south of the state. He graduated from the University of Western Australia with a degree in Biochemistry and Microbiology and from the University of Oxford with a D.Phil. in Immunology in 1992. He was a postdoctoral fellow in immunology at Stanford University School of Medicine and he joined the faculty at the University of California, San Francisco in 1995.

Mariapia Degli-Esposti 

Mariapia Degli-Esposti received a PhD in immunology and immunogenetics from the University of Western Australia (UWA) and then trained at Immunex, Seattle, USA. She returned to Australia in 1998 and has since held appointments at the University of Western Australia as an NHMRC Research Fellow. She is currently the Director of Research at the the Lions Eye Institute and the Head of the Immunology Division at the Centre for Ophthalmology and Visual Sciences at UWA.

The focus of her research has been to understand the regulation of complex immune responses, especially those elicited during chronic viral infection and autoimmunity. Over the last 15 years, using cytomegalovirus infection as a model, her laboratory has made a number of seminal contributions to understanding the interactions between innate and adaptive immune responses and how they contribute to the outcome of infection. Her research has included defining novel immunoregulatory roles of NK cells. This research has important implications in understanding the cause and potential treatments of diseases, including ocular diseases, which have an immunological component.

Vishva Dixit

Vishva Dixit_SmallVishva M. Dixit, M.D.
 is Vice President of Physiological Chemistry at Genentech, Inc. His interests include cell death, NF-kB signaling, role of ubiquitin modification in disease pathogenesis, and characterizing regulatory complexes within the innate immune system, especially, the Inflammasome.

A historical perspective of his contributions is documented in three accounts published in Nature (2008, 453:271-273), Nature Cell Biology (2010, 12(5): 415) and The Journal of Immunology (2013, 190:3-4).

He is a Foreign Member, European Molecular Biology Organization, a member of the Institute of Medicine, the American Academy of Arts and Sciences and the National Academy of Sciences.

Anne Durandy

Anne DurandyAnne Durandy, a MD, PhD, is to-day an emeritus research director at Imagine Institute at Necker University hospital in Paris. From the beginning of her career, she has been strongly involved in the study of lymphocyte development in normal and pathological conditions. Through the genetic and pathophysiological dissection of inherited immunodeficiencies, she contributed to the delineation of molecular mechanisms essential for the specific immune response, especially for the antibody maturation process. 

Sidonia Fagarasan

Sidonia Fagarasan_smallSidonia Fagarasan’s research addresses the symbiotic relationships between gut bacteria and the immune system. She holds an M.D. degree from University of Medicine and Pharmacy, Cluj, Romania and a Ph.D. degree from Kyoto University. Currently a team leader at the RIKEN Center for Integrative Medical Sciences, Yokohama Japan, she has co-authored more than 50 research papers in international peer-reviewed journals, many of which are in high- impact journals such as Science, Immunity, Nature, Cell, and Proceedings of National Academy of Sciences and has received numerous awards.

James Ferrara

James Ferrara_smallDr. Ferrara is a physician-scientist whose clinical and research career has focused on the immunology of bone marrow transplantation (BMT), particularly its major complication graft-versus-host-disease (GVHD). Using trailblazing proteomic techniques, his team has identified and validated unexpected biomarkers for skin, gut and steroid-resistant GVHD. His pioneering mechanistic studies have illuminated unexpected interactions between the innate and adaptive immune systems and have led to both conceptual breakthroughs and the discovery of novel therapeutic targets. A superb clinician and world-class clinical investigator, his decades-long focus on GVHD has significant potential impact in making BMT safer and more effective for all patients. Previously at Harvard and the Universityof Michigan, in 2014 Dr. Ferrara joined Mout Sinai to become the Ward-Coleman professor of Cancer medicine and to direct the Center for Translational Resarch in Hematologic Malignancies.

Richard Flavell

Richard Flavell_smallDr. Richard Flavell is an Investigator of the Howard Hughes Medical Institute and a Sterling Professor and Chairman of the Immunobiology Department at Yale University School of Medicine.   Dr. Flavell’s laboratory studies the molecular and cellular basis of the immune response and has discovered the role of several receptor families in the innate immune response, including Toll-like receptors and intracellular Nod-like receptor families (NLRs).  Recently he has established the connection between inflammasomes, microbial homeostasis and chronic diseases. He showed that dysbiosis of the microbiota leads to IBD and Metabolic Syndrome, including Obesity Fatty Liver disease and Type 2 diabetes.

Reinhold Förster

Reinhold Förster_smallReinhold Förster is Full Professor of Immunology at Hannover Medical School, Germany. He received his Dr med. vet. degree from the University of Munich, Germany,and has been a research associate at the Max Delbruck Center in Berlin, Germany, and an Associate Professor at the University of Erlangen, Germany. He is a European Research Council (ERC) grant awardee and directs the Institute of Immunology where his research focuses on mechanisms of lymphoid-organ organization, with a particular focus on chemokine receptors. More recently, he and his group have investigated the behaviour and dynamics of immune cell migration using two-photon intravital microscopy.

Ian Frazer

Ian Frazer_small 2Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with The University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence in-post as CEO of the Translational Research Institute. He retains an active research program at the Institute in immune responses to cancer and cancer immunotherapy.

Doriana Fruci

Doriana Fruci_CROPPED_smallDoriana Fruci studied Sciences in Biology at Rome University and received the
specialization in Medical Genetics in 1998, before leaving for a 3 year post-doc at INSERM U25 (Paris, in Peter Van Endert’s lab). Since 2002 she is a Principal Investigator at the Bambino Gesù Children Hospital. In her post-doctoral studies, her work led to the identification of endoplasmic reticulum aminopeptidases, ERAP1 and ERAP2, that trim peptides in the endoplasmic reticulum before binding to MHC class I molecules. Her team is currently interested in the role of ERAP1 in tumor rejection, and how the manipulation of this peptidase may impact the innate and adaptive anti-tumor immune responses. Doriana Fruci also focused her research to define the role of tumor-infiltrating immune cells in mediating control of cancer growth.

Stephen Galli

Stephen Galli_smallStephen J. Galli, MD is Chair and Professor of Pathology at Stanford University. He investigates the roles of mast cells and basophils in health and disease, including allergic disorders. He was President of the American Society for Investigative Pathology (ASIP, 2005-2006) and belongs to several honorary societies including the Collegium Internationale Allergologicum (serving as President from 2010-2014), the Institute of Medicine of the U.S. National Academy of Sciences, and the Accademia Nazionale dei Lincei in Rome. In 2014, he received the Rous-Whipple Award of the ASIP and the Karl Landsteiner Medal of the Austrian Society of Allergology and Immunology.

Katharina Gaus

Katharina GausScientia Professor Katharina Gaus is an NHMRC Senior Research Fellow at the University of New South Wales and Head of the EMBL Australia Node in Single Molecule Science. She received her PhD from the University of Cambridge in 1999 and has led an independent research group since 2005. Her group investigates T cell signalling with advanced fluorescence microscopy. She was awarded the Young Investigator Award from the Australia and New Zealand Society for Cell and Developmental Biology (2010), the Gottschalk Medal from the Australian Academy of Science (2012) and the New South Wales Science and Engineering Award for Excellence in Biological Sciences (2013).

Anna George

Anna GeorgeAnna George: did a Ph.D. from Bombay University and postdoctoral research at the University of Pennsylvania in Philadelphia and the Royal Postgraduate Medical School in London. After a short stint as an independent researcher at the National Institute of Dental Research at the NIH, she joined the National Institute of Immunology in New Delhi as a Staff Scientist in 1996 and has been there since. The broad aim of her laboratory is to track the generation and maintenance of immune responses following infection or immunization and to study the nature of immune homeostasis, and its disruption, in the gut.

Ronald Germain

Ronald GermainRonald N. Germain received his M.D. and Ph.D. from Harvard University. Since then time, he has investigated basic immunobiology, first on the faculty of Harvard Medical School and, since 1982, as the Chief, Lymphocyte Biology Section in the Laboratory of Immunology and now as Chief of the Laboratory of Systems Biology at NIAID, NIH. He has made key contributions to our understanding of MHC class II molecule structure–function relationships, the cell biology of antigen processing, and the molecular basis of T cell recognition. More recently, his group has been building a more complete picture of the immune system by utilizing dynamic and advanced static imaging technologies in combination with systems methods and computational modeling.

Florent Ginhoux

Florent Ginboux_smallFlorent Ginhoux graduated in Biochemistry from the University Pierre et Marie CURIE (UPMC), Paris VI, obtained a Masters degree in Immunology from the Pasteur Institute in 2000 and his PhD in 2004 from UPMC, Paris VI. As a postdoctoral fellow, he joined the Laboratory of Miriam Merad in the Mount Sinai School of Medicine (MSSM), New York. In 2008, he became an Assistant Professor in the Department of Gene and Cell Medicine, MSSM and member of the Immunology Institute of MSSM. He joined the Singapore Immunology Network (SIgN), A*STAR in May 2009 as a Principal Investigator. He is an EMBO Young Investigator and his laboratory is focusing on the ontogeny and differentiation of macrophages and dendritic cells in both humans and mice.

Laurie Glimcher

Dr Glimcher_smallDr. Glimcher is the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College in New York, where she is also Professor of Medicine. In addition, she is Provost for Medical Affairs of Cornell University. Previous to her current positions, she was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, where she was director of the Division of Biological Sciences, and Professor of Medicine at Harvard Medical School, where she headed the immunology program. She also served as Senior Physician and Rheumatologist at the Brigham and Women’s Hospital. As an immunologist, her primary research interests are elucidating the molecular pathways that regulate CD4 T helper cell development and activation, critical for both the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. She is a Fellow of the American Academy of Arts and Sciences, a Member of the Institute of Medicine of the National Academy of Sciences and a Member of the National Academy of Sciences. She is a member of the American Asthma Foundation, Health Care Ventures, and Cancer Research Institute Scientific Advisory Boards and served on the Burroughs-Wellcome Fund and HHMI Scientific Advisory Boards. She sits on the Board of Trustees of Cornell University, the Board of Overseers of Weill Cornell Medical College, the Board of Trustees of Memorial Sloan Kettering Cancer Center and the Board of Directors of the New York Blood Foundation and is on the Corporate Board of Directors of the Bristol-Myers Squibb Pharmaceutical Corporation and the Waters Corporation. Dr. Glimcher speaks nationally and internationally on rheumatology, immunology, skeletal biology and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.

Ananda Goldrath

Ananda Goldrath_smallProfessor Goldrath attended University of Washington Immunology graduate program where she trained with HHMI Professor Michael Bevan. She then completed her postdoctoral training with Professors Christophe Benoist and Diane Mathis at Harvard Medical School. In 2004 she joined the faculty of University of California San Diego in the Division of Biology where her laboratory works to understand how immunological memory is generated and maintained.

Christopher Goodnow

Chris Goodnow_editedChristopher C Goodnow FAA FRS holds the Bill and Patricia Ritchie Foundation Chair and is Deputy Director, NHMRC Australia Fellow, and Head of the Immunogenomics Laboratory at the Garvan Institute of Medical Research in Sydney, Australia. He is known particularly for research that has illuminated how the body’s immune system learns to distinguish “self” from “not-self” so that it does not attack our own body or cause cancer while fighting off infections. Using experimental tools of mouse molecular genetics and genome sequencing, he has pioneered new ways to reveal how the body’s phenotype results from its’ genotype – “phenomics.”

Gillian Griffiths

Gillian Griffiths_smallProfessor Gillian Griffiths FMedSci, FRS obtained her PhD at the MRC Laboratory of Molecular Biology in 1984, with Cesar Milstein. She started her own lab at the Basel Institute for Immunology before moving to University College London, the Dunn School of Pathology, Oxford, and the Cambridge Institute for Medical Research (CIMR) where she is now Director. She was elected as a Fellow of the Academy of Medical Sciences in 2005, a member of EMBO in 2006, and a Fellow of the Royal Society in 2013. Gillian’s research interests are focused on understanding the cell biology of polarised secretion from lymphocytes.

Hamida Hammad

Inflammation Research Center (IRC)

More information coming soon.

John Harty

John Harty_cropped_smallDr. John Harty received his PhD from the University of Minnesota with Peter Plageman studying viral pathogenesis and did postdoctoral research in T cell biology at the University of Washington with Michael Bevan.  He is a Professor of Microbiology, Pathology and the Interdisciplinary Graduate Program in Immunology and holds the Mark Stinski Endowed Chair in Microbial Immunology at the University of Iowa.  His research interests lie in understanding T cell immunity to pathogens, including the global health threats of malarial disease and influenza virus infections.

Helen Heslop

Helen Heslop_smallHelen Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. Her initial studies were the first to demonstrate that antigen-specific cytotoxic T cells could eradicate an established malignancy and because the cells were genetically marked, she and her collaborators obtained definitive evidence of cell expansion, trafficking to tumor sites and decade-long persistence. Subsequent protocols have extended this approach to Hodgkin’s Disease, NHL and nasopharyngeal cancer. An additional focus in reconstituting antiviral immunity post transplant She was a Doris Duke distinguished clinical research scientist and serves as Principal Investigator on several peer-reviewed research programs, including an NCI-funded program project grant (Enhancing T-Cell Therapy of Cancer) a Leukemia and Lymphoma Society Specialized Center of Research (SCOR) award (Immunotherapy of Lymphoma) and a SPORE in lymphoma from the NCI. She is the current President of the Foundation for Accreditation of Cell Therapy (FACT).

Geoff Hill

Prof Geoff Hill is a medical graduate of the University of Auckland and Haematologist, training in New Zealand, The Dana Farber Cancer Institute, and Harvard Medical School in Boston. He is a NHMRC Senior Principal Research Fellow and his immunology laboratory focuses on the interactions between cytokines, antigen presenting cells and regulatory cells during transplantation. 

Prof Hill was the 2005 Queenslander of the Year and recipient of the Transplantation Society of Australia and New Zealand 2009 Ian McKenzie Award for excellence within basic and clinical research in the transplant field. He was also awarded a Queensland Health Senior Clinical Research Fellowship in 2010 to translate new therapies into clinic practice; and in 2011 received a prestigious five year NHMRC Australia Fellowship.  In 2014 he was awarded the inaugural Translational Research Institute National Prize for research improving health outcomes for patients.  In 2015 he was elected to the Australian Academy of Health and Medical Research.

 Phil Hodgkin

Phil Hodgkin

Phil Hodgkin is the current head of the Immunology Division at WEHI, Melbourne. His primary interest is decision-making by T and B lymphocytes when under the influence of multiple different signals. His laboratory has identified a series of rules for a cellular calculus that can help predict the outcome of adaptive immune responses for therapeutic benefit. To interrogate cells under controlled conditions his laboratory develops and uses quantitative methods based on single cell imaging and division-based tracking. His laboratory also develops analytical tools based on the cellular calculus to predict the effect of cytokines and genetic changes on lymphocyte growth, survival and differentiation.

Kris Hogquist

Kris Hogquist_smallDr. Hogquist obtained her bachelor’s degree in Biology from the College of St. Catherine (St. Paul, MN) and doctoral degree in Immunology from Washington University (St. Louis, MO). She did post-doctoral work the University of Washington (Seattle, WA), where she first became interested in T cell development. She started as an Assistant Professor at the University of Minnesota in 1995, and currently holds the David M. Brown Endowed Professorship in the Department of Laboratory Medicine and Pathology there, and is the Associate Director of the Center for Immunology. Her research program is focused on T cell development in the thymus, particularly positive and negative selection, tolerance, and the human immune response to chronic infection. She has received several awards for her research, including the JV Satterfield Arthritis Investigator Award, a Searle Scholar Award, and an NIH MERIT award; and is highly active in the Immunology community, serving on many editorial boards, advisory and grant review panels, and conferences chairs.

Marc K. Jenkins

Marc JenkinsMarc Jenkins received his Ph.D. in Microbiology and Immunology in 1985 from Northwestern University and then conducted postdoctoral training in the Laboratory of Immunology at the National Institutes of Health. He joined the Microbiology Department at the University of Minnesota in 1988, where he conducts research on antigen-specific helper T cells and B cells in the Center for Immunology. He received the Pew Scholar in the Biomedical Sciences Award, the American Association of Immunologists Meritorious Career Award, and an NIH Merit Award. Dr. Jenkins is a past President of the American Association of Immunologists.

Eun-Kyeong Jo


Eun-Kyeong Jo_smallProf. Eun-Kyeong Jo leads “Infection Signaling Network Research Center (ISNRC)” at Chungnam National University (CNU, Korea) since 2007. She gained her M.D. (1991) and Ph.D. degree (1996) from College of Medicine, CNU. After postdoctoral training at Imperial College London, she was promoted to professor at CNU in 2008. She has published over 110 publications in highly peer-reviewed journals and currently serves as Director of ISNRC. Her research interests are innate immune regulation and autophagy in mycobacterial infection. She also focuses on several key functions of orphan nuclear receptors in regulation of innate immunity and inflammation.

Simon Jones

Simon Jones_smallProfessor Simon Jones is currently Associate Director for the Cardiff Institute of Infection and Immunity in the School of Medicine in Cardiff University where he leads the inflammation research group. He has a PhD in Biochemistry from Bristol University. He has since developed a research program focused on the cytokine pathways that determine balance between competent host defense and inflammation induced tissue damage. Studies explore the control of innate and adaptive immunity and the contribution of stromal tissue in determining disease outcomes.

Carl June

Carl June_smallCarl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania, and is an Investigator of the Abramson Family Cancer Research Institute. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology with Dr. E. Donnell Thomas and Dr. John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 – 1986. He is board certified in Internal Medicine and Medical Oncology. He founded the Immune Cell Biology Program and was head of the Department of Immunology at the Naval Medical Research Institute from 1990 to 1995 before joining the faculty of the Perelman School of Medicine in 1999. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. He has published more than 300 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012, the William B Coley award, and the Richard V Smalley Memorial Award from the Society for Immunotherapy of Cancer in 2013. In 2014 he was elected to the American Academy of Arts and Sciences.

Susan Kaech 

Susan KaechMemory T and B cells constitute our primary system of defense against reoccurring infectious disease and the ability to form these cells is the ultimate goal of vaccination. Dr Kaech’s laboratory aims to understand how memory T cells are generated during infection and vaccination, and why, in some circumstances, an immunization fails to induce long-term T cell immunity. They are also learning how T cells are regulated in tumor microenvironments to better understand how their functions become suppressed as they infiltrate tumors in order to develop new methods of immunotherapy that enhance anti-tumor responses. Using several powerful model systems of infection or cancer in mice, they are elucidating mechanisms involved in the development of protective and long-lived memory T cells that form after acute infection or conversely, of dysfunctional or “exhausted” T cells that form in tumors or during chronic viral infections. Their studies are aimed at identifying the signals and genetic pathways that regulate the differentiation of T cells in these different types of environments so that they can design new ways to optimize the formation of highly functional, protective memory T cells to fight infection and cancer.

Jorge Kalil

Jorge Kalil_smallJorge Kalil is Professor, School of Medicine, University of Sao Paulo, Director Instituto Butantan and President International Union of Immunological Societies. Graduated in Medicine, Doctor of Science at Jean Dausset’s laboratory (Nobel Prize for HLA). He is Doctor Honoris Causa by Université Paris Sorbonne. He was visiting Professor, Stanford School of Medicine and International Scholar of Howard Hughes Medical Institute. Kalil is dedicated to study mechanisms of immune recognition. He published over 450 articles (ISI) besides several patents. He was decorated as Brazilian Grand Cross – National Order of Scientific Merit and as Chevalier – French National Order of Merit.

Stefan Kaufmann

Stefan Kaufmann_smallStefan H. E. Kaufmann, PhD, is founding director of the Max Planck Institute for Infection Biology, Berlin, Germany, where he heads the Department of Immunology. He is also Professor for Microbiology & Immunology at the Charité, Berlin and Doctor Honoris Causa from the Université de la Mediterranée, Marseille, France. He is former President of the German Society for Immunology and the European Federation of Immunological Societies, and Past President of the International Union of Immunological Societies. He is interested in immunity to tuberculosis (TB) and rational vaccine and biomarker design. He has co-developed a TB vaccine candidate which has completed a phase II-clinical trial. He thus tries to combine basic and applied research with a focus on mycobacterial ligands that stimulate innate immunity, mechanisms underlying antigen presentation, apoptosis and autophagy in TB and the role of cytokines and chemokines as well as T cells and myeloid cells in pathogenesis and protection in TB.

Shigeo Koyasu

Shigeo Koyasu_smallDr. Shigeo Koyasu received his D.Sc. degree from the University of Tokyo. He has served as Research Associate at the Tokyo Metropolitan Institute of Medical Science, Instructor, and Assistant Professor of the Department of Pathology, Harvard Medical School, Associate Professor of Medicine, Harvard Medical School, and Professor and Chairman of Microbiology and Immunology, Keio University of Medicine. He is currently Executive Director for Research of RIKEN and Director of RIKEN Center for Integrative Medical Sciences (IMS). He has been a council member of the International Union of Immunological Societies (IUIS) and treasurer of the Federation of Immunological Societies of Asia and Oceania (FIMSA).

Vijay K Kuchroo

Vijay Kuchroo_smallDr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. Vijay Kuchroo is also an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He was just named the Director of the newly formed Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases – particularly the role of co-stimulation – the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction. His laboratory has made several transgenic mice that serve as animal models for human multiple sclerosis. Dr. Kuchroo first described the inhibitory receptor TIM-3, which is being exploited as a target for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which has been shown to induce multiple different autoimmune diseases in humans. He has published over 325 original research papers in the filed of Immunology and a paper describing development of Th17 authored by Dr. Kuchroo has been one of the highest cited papers in Immunology.

Tomohiro Kurosaki

Tomohiro Kurosaki_smallAfter receiving his PhD from Kyoto University in 1987, he took several positions; including as Research Associate at Sloan-Kettering Institute, Senior Research Scientist at Lederle Laboratories, and Professor at Kansai Medical University. Since 2004, he has served as Group Director of Laboratory for Lymphocyte Differentiation at RIKEN Research Center for Allergy and Immunology (renamed as RIKEN Center for Integrative Medical Sciences in 2013). In 2008, he joined the WPI Immunology Frontier Research Center, Osaka University, as Principal Investigator and has lead Laboratory of Lymphocyte Differentiation ever since. His main research interest is activation mechanism of B lymphocytes.

Riitta Lahesmaa

Riitta LahesmaaProfessor Riitta Lahesmaa, M.D., Ph.D. was a postdoctoral fellow at Stanford University Medical Center 1990-1993 and a Principal Scientist at Roche Bioscience in Palo Alto, California 1993-1998. Since 1998 she has been Director of Turku Centre for Biotechnology, Turku, Finland ( She also is Director of BioCity Turku Centre for Systems Biology and Vice Director of Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology. Dr. Lahesmaa’s research is focused on molecular systems immunology and stem cell biology and aims at understanding molecular mechanisms of type 1 diabetes and other human immune mediated diseases (

Bart Lambrecht

Bart Lambrecht_smallBart N. Lambrecht obtained an MD (1993) and PhD (1999) in Medicine at Ugent and specialized in Pulmonary Medicine (2002) at Erasmus University Medical Center in Rotterdam, The Netherlands. In 2005 he became Professor of Medicine at ErasmusMC, and in 2007 returned to Belgium on an Odysseus grant of the Flemish government, and became professor of Pulmonary Medicine at UGent and UZ Gent. In 2012 he became director of the VIB Inflammation Research Centre (IRC) in Gent. He is an ERC grant awardee and serves as associate editor of Mucosal Immunology, Trends in Immunology and advisory editor of Journal of Experimental Medicine. He has (co)authored more then 200 papers in the field of asthma and allergy. The thematic area of his group is centered around unraveling the role of antigen presenting cells in the lungs. In 2014, he won the famous Scientific Francqui award.

Antonio Lanzavecchia

Antonio Lanzavecchia_smallAntonio Lanzavecchia earned a degree in Medicine from the University of Pavia where he specialized in Pediatrics and in Infectious Diseases. From 1983 to 1999 he was member of the Basel Institute for Immunology and since 1999 he has been the founding director of the Institute for Research in Biomedicine in Bellinzona, Switzerland. He taught Immunology at the Universities of Genoa and Siena and since 2009 is professor of Human Immunology at the ETH Zurich. Dr. Lanzavecchia has published more than 300 papers. His research has covered several aspects of human immunology: from antigen processing and presentation to dendritic cell biology, from lymphocyte activation and traffic to immunological memory and human monoclonal antibodies.

Mark Larché

Mark LarcheMark Larché completed his PhD in Immunology in 1990 (University of London) and post-doctoral fellowships at St. Jude Children’s Research Hospital, Memphis, TN (USA) and St. Mary’s Hospital Medical School (UK), prior to joining the faculty of Imperial College London (1995). In Sept 2006 he moved to McMaster University, Hamilton, Ontario, Canada. He has been the recipient of several international prizes including “The Respiratory 2000 International Young Investigator Award”, “The Henning Lowenstein Research Award 2000” and the “Pharmacia Allergy Research Foundation Award” (2001). He is a co-founder of Circassia Pharmaceuticals PLC, a company developing peptide immunotherapy for chronic inflammatory diseases.

Sharon Lewin

Sharon Lewin_smallSharon Lewin is an infectious diseases physician and basic scientist. She is the inaugural director of the Doherty Institute for Infection and Immunity at the University of Melbourne; consultant physician, Alfred Hospital, Melbourne, Australia; and an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellow. Her laboratory focuses on strategies to cure HIV infection and the pathogenesis of HIV-hepatitis B co-infection. She was the local co-chair of the XXth International AIDS Conference (AIDS2014) which was held in Melbourne July 2014 and was the largest health conference ever held in Australia. She is on the leadership team of the International AIDS Society’s Strategy Towards and HIV Cure and a member of the Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmitted Infections.

Bernard Malissen

Bernard MalissenTeam leader at Centre d’Immunologie de Marseille Luminy ( and Director of Centre for Immunophenomics (

Bernard Malissen pioneered gene transfer approaches to dissect the function of MHC molecules and of the TCR. He demonstrated the occurrence of chromosomal inversion during TCR gene rearrangements and elucidated the atomic structure of an alloreactive TCR in complex with its ligand. Via mutations in the LAT adaptor, he showed that autoimmunity can result from malfunction of negative feedback loops that normally downregulate T cell responses. His recent interests involve the dendritic cells and macrophages that are present in skin and combined high-throughput “omic” approaches and genetic screens to identify novel components of the TCR signaling network.

Fabienne Mackay

Fabienne Mackay_cropped_smallProfessor Fabienne Mackay obtained her PhD from Louis Pasteur University in Strasbourg, France. She is Head of the Inaugural School of Biomedical Sciences in the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia. Her laboratory dissected the functions of BAFF and its receptors in health and disease, findings described in very highly cited articles. A BAFF inhibitor was approved by the FDA on March 9th 2011: a first new treatment for lupus in over 50 years.  She received the Thomson Reuters Australia citation and innovation award and a trophy from the French Ministry of Foreign Affairs in Paris for outstanding contribution in education and research as an expatriate.

Alberto Mantovani

Alberto Mantovani_cropped_smallAlberto Mantovani, MD, is Professor of Pathology at the Humanitas University in Rozzano and Scientific Director of the Istituto Clinico Humanitas.  He has contributed to the advancement of knowledge in the field of Immunology formulating new paradigms and identifying new molecules and functions. He has received several national and international awards. For several years now, bibliometric analyses have indicated that he is the most quoted Italian scientist.  As of January 2015   he has had over 69.000 citations (Scopus). A recent ranking indicates that he is the most quoted Italian scientist working in Italy  and one of the 10 most quoted immunologists (H-index ISI 111; Scopus 134). 

James McCluskey

James McClusky_smallJames McCluskey is Deputy Vice Chancellor Research and Professor in Microbiology and Immunology at The University of Melbourne. His research focuses on immunogenetic control of immunity. He received the Rose Payne Award from the American Society for Histocompatibility and Immunogenetics, the Ceppellini award from the European Federation for Immunogenetics, the International Roche Organ Transplantation Fund Prize for Excellence in Organ Transplantation, and an Australian Museum Eureka award for scientific Research. He is a director of a number of medical research institutes. He led the development of the Peter Doherty Institute for Infection and Immunity at The University of Melbourne.

Ira Mellman

Ira Melllan_smallIra Mellman came to Genentech in the Spring of 2007 as Vice President of Research Oncology, after more than 20 years as a faculty member at the Yale University School of Medicine, where he was chair of his department (Cell Biology), a member of the Ludwig Institute for Cancer Research, scientific director of the Yale Cancer Center, and Sterling Professor of Cell Biology and Immunobiology. Dr. Mellman has a BA from Oberlin College & Conservatory, a PhD in Genetics from Yale, and performed postdoctoral work at the Rockefeller University with Ralph Steinman and Zanvil Cohn. Dr. Mellman’s laboratory is known not only for advances in fundamental cell biology particularly in the area of membrane traffic (including the discovery of “endosomes”) but also for applying these insights to understanding the cellular basis of the immune response, especially dendritic cell function. While at Yale, these interests led to his having founded CGI Pharma, which was recently purchased by Gilead. Ira ran all of oncology research at Genentech until the end of 2013 when he decided to concentrate his efforts on the rapidly developing area of cancer immunotherapy and became Vice President of Cancer Immunology, building a new discovery and development organization to support this effort, which now already accounts for 50% of Genentech’s oncology portfolio. Ira is a member of the US National Academy of Sciences, American Academy of Arts & Sciences, the European Molecular Biology Organization, and the former Editor in Chief of the Journal of Cell Biology. He has also served on the editorial boards of Cell, the Journal of Experimental Medicine, EMBO Journal, among others. He is an elected member of the boards of the Society for the Immunotherapy of Cancer, the American Society for Cell Biology, and the Cancer Research Institute. He remains a somewhat frustrated composer and songwriter, and has recorded two CDs in the little-known genre of “bio-rock”.

Kingston Mills

Kingston Mills_smallKingston Mills is Professor of Experimental Immunology, School of Biochemistry and Immunology, Trinity College Dublin (TCD). He is Head of the Immunology, Inflammation and Infection research theme at TCD. He trained at as a Postdoctoral Fellow at University College London and the NIMR, Mill Hill, London, before joining the Scientific Staff of NIBSC, Herts, UK. He was appointed to a Personal Chair at Trinity College Dublin in 2001 and was Head of the School of Biochemistry and Immunology from 2008-2011. He heads an active research team focusing on T cells in infection and autoimmunity.

Kensuke Miyake

Kensuke Miyake_smallKensuke Miyake is a professor of the Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo. He graduated from Okayama University Medical School in 1984, and obtained Ph.D. at Osaka University Medical School in 1988. He joined the laboratory of Dr. Paul W. Kincade as a postdoctoral fellow in Oklahoma Medical Research foundation from 1988-1990. He then returned to Japan and joined the laboratory of Dr. Masao Kimoto in the Department of Immunology, Saga Medical School in1990. He moved to the University of Tokyo in 2001, and has been in the current position.

Ken Murphy

Kenneth MurphyKen Murphy received his MD and PhD at Johns Hopkins School of Medicine in 1984. He then joined the Pathology Department at Washington University School of Medicine, first as a resident, and later as faculty. He has worked here at Washington University School of Medicine ever since on T cell biology and more recently on the biology of dendritic cells.

Michel Nussenzweig

Michel NussenweigDr. Nussenzweig was born in Sao Paulo Brazil on February 10th 1955.  He received a B.S. summa cum laude from New York University in 1976, a Ph.D. degree from the Rockefeller University in 1981 and an M.D. degree from New York University Medical School in 1982. During his PhD Dr. Nussenzweig discovered that dendritic cells are antigen presenting cells. After completing a medical internship, and residency, and infectious fellowship at the Massachusetts General Hospital he joined Dr. Philip Leder in the department of genetics at Harvard Medical School for postdoctoral training.  He returned to Rockefeller University in 1990 as an assistant professor and Howard Hughes Investigator to head an independent laboratory.  He was promoted to professor in 1996 and holds the Zanvil A. Cohn and Ralph M. Steinman Chair of Immunology. He is a member of the Brazilian Academy of Sciences, American Academy of Arts and Sciences, the Institue of Medicine and the US National Academy of Sciences.

Luke O’Neill

Luke O'Neill_smallProfessor Luke O’Neill was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he leads the Inflammation Research Group. He is also the Founder Director of the Trinity Biomedical Sciences Institute. He has a PhD in Pharmacology from the University of London and carried out Post-Doctoral research at Cambridge U.K. on the pro-inflammatory cytokine IL-1 and innate immune signaling. His research is in the area of the molecular basis to inflammatory diseases. He has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, The Irish Society for Immunology medal, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence, the Science Foundation Ireland Researcher of the Year Award and in 2014 the European Federation of Immunology Societies Medal. He was elected a member of EMBO in 2005. In 2014 he was named by Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in both Immunology and Pharmacology/Toxicology. He is a co-founder and director of Opsona Therapeutics, a drug development company working in the area of Toll-like receptors. He is also key member of the Science Gallery, Trinity College Dublin’s outreach facility which runs outstanding exhibitions at the interface of science and the arts.

Virginia Pascual

Virginia Pascual_smallDr. Pascual is co-Director of Baylor Institute for Immunology Research and Director of the Centers for Inflammation and Genomic Medicine. She is a pediatric rheumatologist experienced in translational research focused on autoimmunity and leads both an NIH-funded Autoimmunity Center of Excellence and Human Immunology Program Consortium Center. Studies from her laboratory identified the role of dendritic cells and interferon in pediatric lupus and of cytokines (IL1) in Systemic-onset Juvenile Arthritis, which has led to successful therapies, including FDA-approved IL1 blockers. Dr. Pascual is committed to applying basic immunologic and genomic approaches to identifying pathogenic mechanisms and biomarkers in autoimmune disease.

Ruby Pawankar 

Ruby Pawankar_smallRuby Pawankar is Prof of Allergy, Dept. of Pediatrics, Nippon Medical School, Tokyo, Japan and Guest Professor, Showa University, Tokyo, and St. Johns Medical College India. Graduated from AFMC, post graduated from BJMC, Pune, she trained in Allergy & Clinical Immunology at Nippon Medical School and Juntendo University, Tokyo. Prof. Pawankar is the Past President of the World Allergy Organization (President 2012-2013), Council member of the Collegium International Allergolicum, Chair of ARIA Asia-Pacific, Board member, Interasma and Fellow of several other societies. Besides her clinical and teaching assignments in allergy, her research has focused on the cellular and molecular mechanisms of allergy, impact of environmental pollutants, and novel therapies for allergies. Among her key contributions is the role of gamma delta T cells in allergy, and that of mast cells with increased Fcepsilon receptor expression as a major source of the obligatory pro- allergic Th2 cytokines capable of driving local allergen-specific IgE synthesis. This has resulted in 460 publications. She is an Editor of several journals and books and has organized several international congresses. She is a recipient of prestigious academic awards, including the International Distinguished Fellow Award of the ACAAI and the Pravasi Bharatiya Samman Award of the Govt. of India.

Pablo Pelegrin

Pablo Pelegrin_cropped_smallPablo Pelegrin obtained his PhD in 2003 in comparative immunology studying IL-1 cytokine at University of Murcia (Spain). Then he moved to Prof. Surprenant’s lab (University of Sheffield, UK) sponsored by AstraZeneca, where he specialized on P2X7 in immune cells. In 2007 he moved to The University of Manchester (UK) where he expanded his research on P2X7 and the regulation of inflammasomes. Dr. Pelegrín joined the Biomedical Research Institute of the Hospital “Virgen Arrixaca” (Murcia, Spain) with a grant for emerging research groups in 2009, where he is group leader with the aim to understand the molecular regulation of inflammation.

Josef Penninger

josef Penninger_cropped_smallJosef Penninger, MD was formerly a lead researcher at the Amgen Research Institute in Toronto. In 2002 he accepted the appointment as founding director of the newly established Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences in Vienna, Austria. Major achievements include pioneering insights into the molecular basis of osteoporosis and breast cancer, as well as the study of metastatic spread. His group has also developed the first haploid embryonic stem cells for functional genetics. Using these approaches, Josef Penninger tries to establish basic principles of development and disease pathogenesis. He has authored and co-authored more than 530 scientific papers, of which a large number was published in leading scientific journals such as “Nature” and “Science”. Josef Penninger’s major awards include the Descartes Prize, the Wittgenstein Prize of the Austrian Federal Government, the Ernst Jung Prize for medical excellence, the Award as Elected Fellow of the American Association for the Advancement of Science, the Innovator Award from Era of Hope/DOD and a second ERC Advanced grant.

Hidde Ploegh

Hidde_Ploegh_smallHidde Ploegh was born (1953) in the Netherlands and came to the USA to perform the experimental part of his Ph.D. work in 1977. He returned to Europe in 1980, and after having held positions in Germany (1980-1984) and the Netherlands (1984-1992) he joined the faculty of MIT as full professor in 1992. In 1997 he became the incumbent of the Mallinckrodt Professorship in Immunopathology at Harvard Medical School and taught both undergraduate and graduate immunology as the director of the graduate program in immunology. He was recruited back to MIT in 2005, where he has been at the Whitehead Institute for Biomedical Research.
Dr. Ploegh’s accomplishments span a range of discoveries and approaches. He was the first to report the successful cloning of a cDNA for a human MHC product, which then opened this area of immunology to molecular biological techniques, speeding up the discovery of new polymorphic variants. This work sparked his interest in glycoprotein synthesis and turnover, elements that continue to figure prominently in current work. He also pioneered the use of HLA transgenic mice to examine the properties of human MHC products as restriction elements, a thread that continues to this day through the construction of gene-targeted mice that express Class II MHC-GFP products, and most recently through the application of somatic cell nuclear transfer, together with Jaenisch and colleagues, to construct new mouse models for infectious disease.
Dr. Ploegh has contributed numerous technological innovations and has driven the analysis of antigen presentation using biochemical and cell biological methods. He was the first to appreciate the importance of the intersection between the endocytic pathway and the intracellular trafficking routes of Class II MHC products as key to antigen presentation. His insights into the biosynthesis of glycoproteins not only led to the design and synthesis of small molecules that can be used to selectively perturb these pathways, they also laid the groundwork for the development of assays to measure peptide transport into the ER as a prerequisite for Class I MHC-restricted antigen presentation. Recently he has turned his attention to the use of bacterial sortases as tools to execute transformations on proteins that are genetically impossible: circular proteins, N-to-N fusions, and C-to-C fusions. These technologies were applied to the generation of improved cytokines, and most recently, in conjunction with the isolation of single domain antibodies generated in camelids, to improved tools for cytofluorimetry and non-invasive imaging of immune cells in living animals.

Michael Postow

Michael Postow_cropped_smallDr. Michael Postow is a physician on faculty at Memorial Sloan Kettering Cancer Center in the Melanoma and Immunotherapeutics Oncology Service.  He completed medical school at New York University School of Medicine and internal medicine residency training at Brigham and Women’s Hospital/Harvard Medical School.  He then returned to New York City to pursue a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center where he conducts clinical research with Dr. Jedd Wolchok in melanoma and immunotherapy.  He has led clinical trials involving immunotherapeutic agents, most notably a phase II study of the combination of nivolumab and ipilimumab and investigations into the combination of radiotherapy and immunotherapy.  His translational efforts involve studying immunologic biomarkers associated with response to immune checkpoint inhibition.  He is the Editor-In-Chief for the journal, Clinical Skin Cancer, and he also serves on the editorial board of the Journal for the Immunotherapy of Cancer.  In his spare time, he enjoys playing guitar and piano, skiing, and sailing.

Fiona Powrie

Fiona Powrie_smallFiona Powrie is the Director of Kennedy Institute for Rheumatology and the Translational Gastroenterology Unit, University of Oxford. Her research interests include characterisation of the interaction between the intestinal microbiota and the host immune system and how this mutualistic relationship breaks down in inflammatory bowel disease. Her work has identified the functional role of regulatory T cells in intestinal homeostasis and shed light on their development and mechanism of action. She has also shown that both adaptive and innate immune mechanisms contribute to intestinal inflammation and identified the IL-23 pathway as a pivotal player in the pathogenesis of chronic intestinal inflammation. Her current work seeks to translate findings from model systems into the clinic in inflammatory bowel disease patients. Fiona Powrie received the Ita Askonas Award from the European Federation of Immunological Societies for her contribution to immunology in Europe and the Louis Jeantet Prize for Medicine 2012. She was elected a Fellow of the Royal Society in 2011, EMBO in 2013 and the Academic of Medical Sciences in 2014.

Anne Puel

Anne Puel is an Associate Professor (Director of Research at the INSERM) in the Laboratory of Human Genetics of Infectious Disease (Necker Branch) at the Imagine Institute (Paris, France) and an Adjunct Senior Research Associate at the Rockefeller University (NYC, USA). She is the leader of the team working on human genetics of fungal diseases. Within the last six years, her team has contributed in deciphering the pathogenesis of chronic mucocutaneous candidiasis (CMC) in primary immunodeficiencies, with the discovery of impaired Th17 cells in autosomal dominant hyper IgE syndrome (AD-HIES) patients or autoantibodies against IL-17 cytokines in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome (Journal of Experimental Medicine 2008 and 2010). Since 2011, her team has discovered the first four genetic etiologies of CMC disease (CMCD) with autosomal recessive IL-17 receptor (IL-17RA) and autosomal dominant IL-17F deficiencies (Science 2011), STAT1 gain-of-function mutations (J Exp Med 2011) and autosomal recessive ACT1 deficiency (Immunity 2013). In 2013, her team has discovered discovered AR CARD9 deficiency as the main clinical aetiology of deep dermatophytosis (the New England Journal of Medicine), and more recently AR CARD9 deficiency in patients with invasive Exophiala infections (Journal of Infectious Diseases, 2014).

Hai Qi

Hai Qi_smallDr. Hai Qi received his Bachelor of Medicine from the Beijing Medical University and Ph.D. in Pathology from the University of Texas Medical Branch at Galveston. After postdoctoral training at NIH with Dr. Ronald Germain, he joined the faculty of Tsinghua University in 2009. He is interested in understanding humoral immune regulation and immune cell-cell interactions in physiology and disease. He uses a variety of approaches including genetic mouse models, classical cell immunological methods, two-photon laser scanning microscopy, intravital imaging, and single-cell analyses in his research.

Gwendalyn Randolph

Gwendalyn Randolph_smallGwen Randolph obtained her bachelor’s degree in Biology from Temple University and PhD in Molecular and Cellular Pathology from State University of New York at Stony Brook, working with Martha Furie. She then carried out postdoctoral studies at Rockefeller University and Weill Medical School of Cornell University under the mentorship of Bill Muller and Ralph Steinman. She spent 11 years on the faculty at Mount Sinai School of School of Medicine in New York and is currently Professor of Immunobiology in the Department of Pathology and Immunology at Washington University in St. Louis. Her laboratory studies monocytes, macrophages, and dendritic cells in the context of vascular and lymphatic biology, with a long-standing emphasis on the disease atherosclerosis and an emergent interest in Crohn’s disease.

Cameron Simmons 

Cameron Simmons_smallProfessor Cameron Simmons is a NHMRC Senior Research Fellow and VESKI Innovation Fellow at the University of Melbourne.  Professor Simmons is responsible for leading a productive research team working at the cutting edge of medical science. Professor Simmons is internationally recognised for his work on the prevention and treatment of tropical infectious diseases, particularly dengue, in SE Asia. The centre of gravity for Professor Simmons’ work on dengue prevention and treatment is in Indonesia, Vietnam, Singapore and Thailand.

Caetano Reis e Sousa 

Caetano Reis e Sousa_cropped_smallCaetano Reis e Sousa obtained a BSc(Hons) in Biology in 1989 from Imperial College, London, and a DPhil in Immunology in 1992 from Oxford. He subsequently was a postdoctoral fellow with Ron Germain at the National Institutes of Health, USA. In 1998, he joined the Imperial Cancer Research Fund, later to become Cancer Research UK’s London Research Institute (LRI), as head of the Immunobiology Laboratory. In 2015, the LRI was subsumed into the new Francis Crick Institute where Caetano is currently a Senior Group Leader. He is also Professor of Immunology in the Department of Medicine at Imperial College and holds honorary professorships at University College London and King’s College London. Caetano’s research centres on the regulation of adaptive immunity by antigen-presenting cells, the innate immune mechanisms involved in sensing pathogen presence and cell death and the complexity of the mononuclear phagocyte system. His scientific contributions have been widely recognised and he is included in the list of Highly Cited Researchers (Thomson Reuters 2014) and has won the BD Biosciences Prize of the European Macrophage and Dendritic Cell Society (2002), the Liliane Bettencourt for Life Sciences Award (2008) and the Award for Excellence in Basic/Translational Research from the European Society for Clinical Investigation (2011). He is a fellow of The Academy of Medical Sciences (elected 2006), a member of the European Molecular Biology Organisation (EMBO; elected 2006) and was made an Officer of the Order of Sant’Iago da Espada by his native Portugal in 2009.

Nicholas P. Restifo 

Nick Restifo_cropped_smallNicholas Restifo, MD was educated and trained at Johns Hopkins University, New York University and Memorial Sloan Kettering before joining the National Cancer Institute at the NIH, Bethesda, MD in 1989 where he has remained. 

His entire career has been focused on understanding the fundamental principles of tumor immunology and on developing curative treatments for patients with metastatic cancer. In 2014 he was named by Thomson Reuters as one of the World’s most highly cited immunologists and was also one of the World’s most highly cited authors in clinical medicine.

The focus of Dr. Restifo’s laboratory is on T cells. He has made major contributions toward elucidating the role of T cells in tumor recognition, destruction and escape. His laboratory identified a novel human T stem cell memory subset, and characterized how individual T cell clonotypes possess true stem cell-like behavior. He now seeks to define how transcription factors conditionally control T cell ‘stemness’ by modulating the availability of key enhancer elements.  

Jamie Rossjohn 

Jamie Rossjohn_small

Prof. Rossjohn, NHMRC Australia Fellow at Monash University, is recognised for his contributions to the understanding the function and dysfunction of the immune system.  He has used structural biology to explain T-cell development, and how the T-cell receptor combats viruses, causes autoimmunity, drug and food hypersensitivities. He has pioneered our understanding of lipid-based immunity by T-cells and recently showed how vitamin B metabolites represent an entirely new target for T-cells.

Ellen Rothenberg

Ellen Rothenberg_smallEllen Rothenberg is the Albert Billings Ruddock Professor of Biology at the California Institute of Technology, Pasadena, CA, USA.  She graduated from Harvard University in 1972 and received her Ph.D. from the Massachusetts Institute of Technology in 1977.  She held a Jane Coffin Childs Postdoctoral Fellowship at the Memorial Sloan-Kettering Cancer Center, then started her independent career at the Salk Institute for Biological Studies, before joining the California Institute of Technology faculty in 1982.  Her laboratory studies gene regulation and development of T lymphocytes, gene networks controlling blood cell fates, and mechanisms underlying the dynamics of single-cell developmental decisions.

Sarah Rowland-Jones

Sarah Rowland-Jones_smallSarah Rowland-Jones trained in medicine in Cambridge and Oxford Universities, and then in Infectious Diseases in London and Oxford. Her research in the Nuffield Department of Medicine in Oxford focuses on the role of cellular immune responses to viral infections, particularly HIV-1-specific T-cells and how viral evolution leads to evasion of T-cell recognition. A key focus of the group is the study of patient cohorts, both adults and children, with distinct outcomes of HIV-1/2 infection and exposure, in collaboration with epidemiologists and clinicians in MRC Gambia, Guinea-Bissau, Kenya, USA, Zimbabwe and China. Between 2004-8 she was Research Director of the MRC Laboratories, the Gambia, where her research interests focused on HIV-2 pathogenesis and the development of infant immunity in response to pathogens and vaccines in early life. She is clinically active and holds an Honorary Consultant contract in Infectious Diseases at the Oxford University Radcliffe Hospital Trust, spending 2-3 months/year on clinical service on the adult ID ward.

Alexander Rudensky

Alexander Rudensky_new_smallAlexander Rudensky is Chairman of the Immunology Program and Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center (MSKCC), an Investigator with the Howard Hughes Medical Institute, and a Tri‐Institutional Professor at MSKCC, the Rockefeller University and Cornell University, and Professor at Gerstner School of Graduate Studies and at Weill‐Cornell Medical School. Dr. Rudensky is an internationally-recognized leader in the field of immune regulation, where he has made numerous seminal discoveries including the identification of the molecular mechanisms of regulatory T cell differentiation. Dr. Rudensky was elected to the National Academy of Sciences in 2012.

Shimon Sakaguchi

Shimon Sakaguchi_smallDr. Shimon Sakaguchi obtained M.D. in 1976 from Kyoto University, Japan, was trained as a pathologist and immunologist. He is currently a Distinguished Professor of Osaka University and his lab is in WPI Immunology Frontier Research Center Osaka University. For his contribution to immunology, especially for his discovery of regulatory T cells, he was awarded various prizes including Cancer Research Institute’s William B. Coley Award and the Keio Medical Science Prize, and elected to a Foreign Associate of the National Academy of Sciences USA. His main research interest is in immunological tolerance and immune regulation.

Federica Sallusto

Federica SallustoFederica Sallusto is expert in the field of human cellular immunology. Her main contributions deal with mechanisms that regulate migration and effector function of T lymphocytes. These studies allowed to define Th1, Th2, Th17 and Th22 cells on the basis of chemokine receptors expression and to distinguish central and effector memory T cells. Recently, she clarified mechanisms that generate Th17 lymphocytes with different inflammatory capacity and demonstrated that within a single clone T cells can acquire different functional properties. Her studies in experimental models clarified mechanisms controlling lymphocyte migration in lymphnodes and brain and generation of follicular helper T cells.

Birgit Sawitzki

Birgit Sawitzki (1)_smallProf. Birgit Sawitzki is the scientific director of the Research Center of Immunosciences and a group leader at the Institute of Medical Immunology at the Charité University Hospital in Berlin. Previously she completed a postdoc at the Nuffield Department of Surgery, University of Oxford. She is Council member of the European Society of Organ Transplantation (ESOT). She has developed immune monitoring tools for analysing the immunological profile of transplant patients and is coordinating the immune monitoring of three big multi-centre investigator-driven clinical trials, sponsored by the EC, aiming on personalized treatment and eventually tolerance induction in transplant patients. She has been deciphering mechanisms underlying tolerance induction in preclinical mouse models and in patients.

Feng Shao

HHMI Scientist PortraitsDr. Feng Shao is an investigator and deputy director at National Institute of Biological Sciences (NIBS), Beijing, CHINA. He was a chemistry undergraduate of Peking University and obtained his PhD degree from University of Michigan in 2003. Dr. Shao’s research focuses on biochemical mechanism of bacterial infection and host innate immunity. His laboratory has discovered several novel post-translational modifications used by the bacteria to disrupt host defense. He has also identified cytosolic receptors for bacterial LPS, flagellin and the type III secretion system as well as the Pyrin inflammasome that senses bacterial modifications of Rho GTPases. Dr. Shao‘s work has been recognized by several renowned academic honors including the International Early Career Award from Howard Hughes Medical Institute.

Arlene Sharpe

Arlene SharpeArlene Sharpe M.D. Ph.D. is the George Fabyan Professor of Comparative Pathology at Harvard Medical School, Head of the Division of Immunology in the Department of Microbiology and Immunobiology, Co-Director of the Harvard Institute of Translational lmmunology, and a member of the Department of Pathology at Brigham and Women’s Hospital. Dr. Sharpe earned her M.D. and Ph.D. degrees from Harvard Medical School, and completed her residency in Pathology at Brigham and Women’s Hospital. Dr. Sharpe’s laboratory investigates T cell costimulatory pathways and their immunoregulatory functions. Her laboratory studies the roles of T cell costimulatory and coinhibitory pathways in regulating immune responses needed for the induction and maintenance of T cell tolerance and effective antimicrobial and antitumor immunity. A major focus of her laboratory is elucidating the role of coinhibitory molecules in mediating tissue tolerance and controlling inflammation. Her laboratory is also involved in studies aimed at translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases and cancer.

Michael Sixt

Michael SixtMichael Sixt studied human medicine at University of Erlangen (Germany) where he also worked for two years as a clinical resident. 2003 he joined the laboratory of Lydia Sorokin at University of Lund, Sweden as a Postdoc before, in 2005, he moved to the Max Planck Institute of Biochemistry, Martinsried as a junior group leader. 2010 he joined IST Austria as an Assistant Professor and was promoted to Professor in 2013. Michael Sixt works at the interface between immunology, cell biology and biophysics. Currently, his lab is primarily interested mechanisms of immune cell trafficking with a focus on single cell navigation and locomotion.

Anne Spurkland

Anne Spurkland_smallAnne Spurkland is MD and Professor in Anatomy at the University of Oslo (UiO), Institute for Basal Medical Sciences. Her research efforts are directed towards: 1. Identifying novel genes involved in the susceptibility to multiple sclerosis. Spurkland is a member of the International Multiple Sclerosis Genetics Consortium. 2. Functional characterization of genes associated with autoimmune disease, in particular those relevant for activation and clonal expansion of T cells. Spurkland is a member of The Norwegian Academy of Science and Letters.

Kate Stacey

The University of Queensland

More details coming shortly.

Charles Surh

Charles Surh_smallCharles Surh is the Director of Academy of Immunology and Microbiology (AIM), one of the research centers of Institute for Basic Science (IBS) in Korea. He had spent much of his career at The Scripps Research Institute prior to moving to Korea in 2012. His contribution to T cell biology, especially for defining the factors that regulate T cell homeostasis, has been widely recognized, including the Ho-Am Prize in Medicine in 2007. He has recently widened his scope to investigate how T cells establish homeostasis with the ever-present foreign antigens from the commensal microbiota and dietary components.

Stuart Tangye

Stuart Tangye_smallDr Stuart Tangye is the Head of the Immunology Division at the Garvan Institute of Medical Research, Professor in the Faculty Medicine, University of NSW Australia, and an NHMRC Principal Research Fellow. He completed his PhD on B-cell leukemia at UTS in 1995 and undertook postdoctoral training at the DNAX Research Institute for Molecular and Cellular Biology (Palo Alto California, USA; 19996-1999). He returned to Australia in 2000 as a University of Sydney Research Fellow to work with Dr Phil Hodgkin at the Centenary Institute of Cancer Medicine and Cell Biology (University of Sydney). He established an independent research lab in 2002, and was recruited to the Garvan Institute in 2006.

His research interests focus on human immunobiology in health and disease. This is achieved by studying lymphocyte development, signalling, differentiation and effector function in patients with diseases resulting from monogenic loss- or gain-of-function mutations in key regulators of immune responses, as well as in corresponding animal models of these human conditions. In the past few years, his lab has made significant contributions to elucidating how these mutations result in some of the clinical features that are associated with human primary immunodeficiencies. He has been funded by fellowships and project and program grants awarded by the NHMRC, Cancer Council NSW, XLP Research Trust and Association for International Cancer Research. Since 1995, he has published >135 peer-reviewed articles and invited reviews and in 2011 he received the Gottschalk Medal from the Australian Academy of Sciences, which recognises “outstanding research in the medical sciences by scientists no more than 40 years of age”. More recently he was awarded the Faculty of Science Alumni Excellence Award from the University of Technology Sydney, and a Senior Scholarship from the US-Australian Fulbright Commission to undertake sabbatical study at Rockefeller University in New York. He is on the editorial boards of J Exp Med, J Immunol and J Clin Immunol. When he is not at work, he enjoys surfing, cycling, swimming and most of all being a Dad to his three beautiful children!


Wayne Thomas 

Wayne Thomas_small

Graduating with a PhD in 1974 from the University of Western Australia Professor Thomas studied T cell regulation of IgE and cytokines in London and Melbourne discovering with colleagues at the Walter and Eliza Hall Institute interferon gamma production by antigen-simulated helper T cells. Returning to Perth in 1984 he pioneered the molecular cloning of allergens and the use of peptides and recombinant reagents to investigate and treat common allergies particularly house dust mite. Professor Thomas was senior principal research fellow of the national health and medical research council from 1998-2012 and continues to work at the Telethon Kids Institute.


Shannon Turley

Shannon Turley_smallDr. Turley received her PhD in 1999 from Yale University, and later completed postdoctoral training in immunology at Joslin Diabetes Center in Boston. In 2004, she became Assistant Professor of Pathology at Harvard Medical School and in the Department of Cancer Immunology at Dana Farber Cancer Institute. In 2010 Dr. Turley was promoted to Associate Professor of Microbiology and Immunobiology at Harvard Medical School and Dana Farber Cancer Institute. In 2014, she moved her laboratory to the Department of Cancer Immunology at Genentech.

Dr. Turley received several awards and honors including the Research Scholar Award (2005-­2008) by the American Cancer Society. She was also elected as member of Henry Kunkel Society (2010-2014).

The mission of her research team is to establish a deep understanding of stromal cell function in inflammation and cancer, develop novel approaches to modulate the stromal microenvironment and validate the efficacy of stromal-­‐targeted therapies in augmenting protective immunity. Her laboratory investigates the roles that distinct populations of stromal cells play in mature and aging tissues, and in shaping innate and adaptive immunity. Dr. Turley’s work aims to elucidate molecular circuitries between lymphoid stromal determinants, myeloid cells and lymphocytes that control immune homeostasis, host-­defense, and lymphoid tissue dynamics and repair.

Rudolf Valenta 

Rudolf Valenta_smallRudolf Valenta studied Medicine at the University of Vienna and obtained his MD degree in 1987 with distinction. He then started to work on the molecular characterization of allergens, became Associate Professor at the University of Vienna and founded his research group “Molecular Immunopathology” in 1993. He currently is full Professor for Allergology at the Medical University of Vienna and Foreign Adjunct Professor for Allergy at the Karolinska Institutet, Stockholm, Sweden. He co-ordinated two allergy research programs at the Medical University of Vienna, served as chairman of the standardization committee of the International Union of Immunological Societies (IUIS), as vice-president of the European Academy for Allergy and Clinical Immunology, as president of the Austrian Society for Allergology and Immunology and is member of the Austrian Academy of Sciences. He has been working in the field of allergy research for more than 25 years. Starting with the molecular and immunological characterization of important allergens he continued to develop recombinant allergen-based diagnostic tests as well as therapeutic allergy vaccines based on recombinant allergens and genetically engineered hypoallergens and advanced them into clinical application. He has been awarded several prestigious national and international awards, among them the START Award of the Austrian Science Fund (FWF), the International Pharmacia Award and the Sarstedt Award which he received in 2000 for his work on the genetic analysis of allergy-eliciting substances and their recombinant production (after: J. Klose and P.H. O`Farrell 1986 “Two-dimensional electrophoresis”; H. Towbin, T. Staehelin and J. Gordon, 1988 “Western blot”; M. Wilchek and E. A. Bayer 1990 “Biotin-Avidin system”; F. S. Collins, J. Riordan, L.-C. Tsui 1993 “Cystic fibrosis gene”; B. Vogelstein and D. Sidransky 1997 “Molecular biology of malignant tumors”). Rudolf Valentas work is highly cited (Cumulative citation index: 22.500; h-index: 79), he has published more than 560 original scientific publications, reviews and book chapters, more than 135 patents/patent applications and gave more than 350 invited lectures. He introduced recombinant allergens into diagnosis and treatment of allergic diseases. He is currently working on mechanisms of allergic diseases, the introduction of new diagnostic, therapeutic and preventive concepts for allergy into clinical use and on the characterization of antigens in infectious diseases with the aim to develop diagnostic tests and vaccines also in this area.

Carola Vinuesa

Carola Vinuesa_smallCarola Vinuesa was born in Spain and obtained a medical degree at the University Autonoma of Madrid. She undertook specialist clinical training in the UK and in 2000 was awarded a PhD by the University of Birmingham. A year later she was the recipient of a Wellcome Trust International Travelling prize Fellowship to do postdoctoral work at The John Curtin School for Medical Research in The Australian National University. Her work led to the discovery of genes important for immune regulation and memory and the identification of a novel pathway of posttranscriptional control of gene expression to prevent autoimmunity. Since 2006 she has been leading the Humoral Immunity and Autoimmunity Group at ANU supported by a Viertel Senior Medical Research Fellowship. Her group identified a critical role for follicular helper T (Tfh) cells in autoantibody-mediated autoimmune diseases and contributed to the characterization of this subset and elucidation of their transcriptional regulation. She is currently investigating the mechanisms that regulate Tfh cells and germinal center selection and how to bosst these responses to improve vaccine efficiency while preventing autoimmunity. In 2008 she was awarded the Science Minister’s Prize for Life Scientist of the year and in 2009 the Gottschalk Medal of the Australian Academy of Sciences. She is currently Professor of Immunology at the Australian National University and Head of the Pathogens and Immunity Department.

Eric Vivier

MiLabs Marseille 18/06/2014.©JM Huron.Eric Vivier was trained as a Doctor in Veterinary Medicine and as a PhD in Immunology in Paris. He completed his postdoctoral work at Harvard. He is currently the Director of the Centre d’Immunologie de Marseille-Luminy, where he heads the laboratory of «Natural Killer cells and Innate Immunity». He is a Professor at the Marseille Medical School and a Scholar at the Institut Universitaire de France. His work focuses on Natural Killer cells and Innate Lymphoid cells. He is co-founder of Innate-Pharma where he is collaborating to set-up NK cell-based therapies against cancer, such as the anti-KIR and anti-NKG2A mAbs. Eric Vivier has been elected to the French National Academy of Medicine in 2013 and received several awards including the EFIS Award and the Grand Prix Turpin in Oncology from the French National Academy of Science.

Kathryn Wood

Kathryn Wood_smallKathryn Wood is Professor of Immunology in the Nuffield Department of Surgical Sciences, University of Oxford where she runs the Transplantation Research Immunology Group (TRIG – Her research focuses on tolerance induction at the molecular and cellular level, immune regulation and interactions between the immune system and stem cell derived tissues. Professor Wood is a Fellow of The Academy of Medical Sciences and her research achievements have been recognised internationally, includingreceiving a Gold Medal awarded by The Catalan Society of Transplantation (2011), The Maharshi Sushruta Award (2012) and the TTS Women in Transplantation, Achievement Award (2014). Kathryn was President of The Transplantation Society (2004-2006); was the founding Chair of the Women in Transplantation initiative (WIT – and Editor of Transplantation (1992 – 2014).